Eli Lilly (LLY) stock jetted higher Thursday after the company said its diabetes and weight-loss pill helped patients lose up to 16 pounds over the course of 40 weeks. The news solidifies Lilly's lead in developing an oral treatment for obesity. It …

Microsoft Corp. MSFT is the world’s second-largest company, with a market capitalization of $2.89 trillion. It develops and supports software, services, devices and solutions worldwide. It will report its Q3 2025 earnings on April 30. Wall Street analysts …

… to rise and the biotech IPO market appeared steady. Now, the … companies waiting to launch an IPO and investors looking to buy … ;s all timing based.” While IPOs hang in the balance, other … . Revenue from Novo’s blockbuster GLP-1 obesity and diabetes medications …

IndoSpace plans IPO to monetise logistics assets, … warehouse assets, is planning an initial public offering (IPO) to monetise its portfolio in … more likely to be an IPO, said people with knowledge … such as Everstone, Realterm, GLP and CPPIB, owns more than …

… the COVID-19 pandemic, our initial public offering and our reemergence as a … first and foremost, of course, GLP-1s are contributing to our … from that regard. Clearly, the GLP-1 profitability is less. That … actually be excited about the GLP-1 customer and as you …

… the pricing of its initial public offering of 5,888, … limitations of currently marketed GLP-1 therapies for … anticipated size of the initial public offering and the expected … to the initial public offering, the completion of the initial public offering on the …

… filing for a potential April IPO at a valuation that … #39;s more conservative expected IPO valuation of $3 billion, … Blue Shield agreements, expanded its GLP-1 weight management solution targeting … numbers relating to HingeHealth’s IPO are based on publicly …

… listed company prior to its initial public offering filing with the Nasdaq Global … plays in the diets of GLP-1 users. “What we see … is that people who use GLP-1s are staying with a …

… developments matter, read on. Semaglutide GLP-1 Shortage Over, But ‘ … , the active ingredient in GLP-1 drugs Wegovy and Ozempic … , the active ingredient in GLP-1 drugs Mounjaro and Zepbound … a dizzying pace. An IPO filing from tech-enabled provider …

… to focus solely on its GLP-1-delivering implant technologies. Our … to continue advancing its miniature GLP-1 therapeutic implants. The spin … S-1 to support an IPO for Cortigent. It revised its …